Moderna's Covid-19 vaccine, mRNA-1273, has shown an efficacy of 96% among teens in early data, CEO Stéphane Bancel announced during an earnings call on Thursday.
Moderna's trial in teens, called the TeenCOVE study, includes people ages 12 to 17.
"We are pleased to report this morning an interim update to our TeenCOVE study," Bancel said. "An initial interim analysis of our Phase 2/3 TeenCOVE study of mRNA-1273 showed vaccine efficacy against Covid-19 of 96% and mRNA-1273 was generally well tolerated with no serious safety concerns identified to date."
Moderna’s Covid-19 vaccine is currently authorized for use in people ages 18 and older.